Navigation Links
Medisafe 1 Technologies One-Time Special Dividend Announced
Date:2/20/2013

JERUSALEM, February 20, 2013 /PRNewswire/ --

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company intends to issue the one-time special dividend to all existing shareholders pursuant to the perpetual license sale of technology rights to SAFECODE DRUG TECHNOLOGIES CORP.

The dates of the dividend are as follows.

Ex-Dividend date for its dividend to its Shareholders on April 30 2013, record date on May 3 2013 and the payment date on May 6 2013.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle.  Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.  Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:
Jacob Elhadad , CEO
+972-524440000
Jacob.elhadad10@gmail.com

'/>"/>
SOURCE Medisafe 1 Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medisafe 1 Technologies Announces the Ex-Dividend Date on April 30 2013, Record Date on May 3 2013 and the Payment Date on May 6 2013
2. Medisafe 1 Technologies Signs the $7MM Perpetual License Agreement
3. Medisafe 1 Technologies Announces Delay in Closing $7MM Perpetual License Sale Due to Hurricane Sandy
4. Medisafe 1 Technologies Anticipates a Special Dividend of $0.01 (One Cent) to Each Shareholder of One Common Stock pending the $7MM Perpetual License Sale of Technology Rights
5. Medisafe 1 Technologies in Advanced Negotiations for $7MM Perpetual License Sale
6. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
7. Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
8. Leading Breast Surgeons Highlight Techniques and Visualization Technologies for Improved Clinical and Aesthetic Outcomes at Invuitys Surgeon Educational Symposium
9. TOA Technologies mobile healthcare service solutions unite personalized service and efficiency to deliver an enhanced patient experience
10. Frost & Sullivan: Clinical Trial-based Evidence Vital to Obtain Venture Capital Funding for Wireless Patient Monitoring Technologies
11. Zebra Technologies Connects the Dots Between the Patient Experience and Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York , September 22, 2014 ... (MRI) market has been recently added to Transparency Market ... (MRI) Market: Global Market Analysis, Size, Share & Forecast ... MRI market, which valued US$ 3.9 billion in 2011, ... 2011 to 2017(the forecast period of the report), and ...
(Date:9/22/2014)... 2014  Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical ... today announced it has completed three phase 3 ... Obiltoxaximab is an anti-toxin in development for the ... studies support the safety and tolerability of the ... therapeutic dose. The conclusion of these studies marks ...
(Date:9/22/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... Ophthalmic Devices: Asia to Witness ... at USD 29,171.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... Market Study on Ophthalmic Devices:  Asia  to ...
Breaking Medicine Technology:Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 2Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 3Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Metformin, a ... risk of low levels of thyroid-stimulating hormone (TSH) among ... The researchers cautioned that low TSH levels may ... a cause-and-effect link was not established in this study. ... thyroid (hypothyroidism), there were 495 incidences of low levels ...
(Date:9/22/2014)... The “ Ztylus ” was featured on NewsWatch ... reviews and features the latest technology gadgets and services available ... expert, conducted the review and shared with viewers how it’s ... gives users four lens options for their camera. , The ... Tech Report, which reviews and features the latest technology gadgets ...
(Date:9/22/2014)... 2014 “The Race is On!” for the ... Sunday, October 12, 2014 as it moves to its new ... As the signature fundraising and awareness event for Susan G. ... Phoenix Race for the Cure provides supporters of all ages ... and even sleeping in. , “Moving the Race to ...
(Date:9/22/2014)... perspiration these symptoms are a few of the ... heart rate and plays a crucial role in its ... Aviv University points to an additional complication caused by ... Mammalian Genome , was conducted by Prof. Karen ... of Human Molecular Genetics and Biochemistry at TAU,s Sackler ...
(Date:9/22/2014)... A study led by University of North Carolina at ... the accurate diagnosis of people who are experiencing the ... delusions that define the development of severe mental disorders ... early adulthood and affects about 1 in every 100 ... person can be a life compromised, and the burden ...
Breaking Medicine News(10 mins):Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Lack of thyroid hormone blocks hearing development 2Health News:Blood test may help determine who is at risk for psychosis 2
... HOUSTON - A vaccine that turns the immune system ... drives the most aggressive form of glioblastoma multiforme improved ... researchers at Duke University and The University of Texas ... Journal of Clinical Oncology . Eighteen newly diagnosed ...
... Oct. 6, 2010 A set of proteins found in ... to diagnose Alzheimer,s disease, researchers at UT Southwestern Medical Center ... An analysis of the proteins, plus a clinical exam, proved ... accurate in ruling it out in people without the disease, ...
... Reinberg HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay ... young adults admit they are binge drinkers, health officials said ... as having four or more drinks for women, and five ... -- numbers that are different because men and women metabolize ...
... to a discovery by a Saint Louis University researcher, scientists ... better control cholesterol levels in blood. Led by ... at Saint Louis University and published in a recent issue ... of the United States of America, the study found that ...
... New neuroscience research by life scientists from UCLA and Australia may ... to brain injury or disease. By examining how ... way the brain first captures and encodes a situation or event ... The study is published in the Sept. 29 edition ...
... By Randy Dotinga HealthDay Reporter , ... study is the latest to suggest that testosterone may ... causing serious side effects. Researchers aren,t yet ready ... to female patients. However, the treatment does hold some ...
Cached Medicine News:Health News:Vaccine extends glioblastoma patients' survival in phase II trial 2Health News:Blood test could diagnose Alzheimer's disease, UT Southwestern researchers find 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 3Health News:Better cholesterol drugs may follow Saint Louis University researcher's breakthrough 2Health News:Neuroscience research may help patients recover from brain injury 2Health News:Testosterone Could Boost Health of Heart Failure Patients 2
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: